Previous 10 | Next 10 |
AC Immune SA (NASDAQ: ACIU ) has announced dosing of the first subject in a Phase 1 study of ACI-3024, an investigational oral small molecule Tau Morphomer inhibitor to address neurodegenerative diseases that are characterized by the presence of pathological Tau aggregates. More news on:...
LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small molecule Tau Morphomer...
Anti-Abeta vaccine demonstrates strong safety and preliminary immunogenicity results in subjects with Down syndrome Presentations underscore significant need and opportunity for studying Alzheimer’s disease-like symptoms in this high-risk and genetically homogeneous population...
LAUSANNE, Switzerland, June 28, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced that shareholders in the Company have elected Douglas Williams as Chairman of ...
LAUSANNE, Switzerland, June 27, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering precision medicine in neurodegenerative diseases, today announced that it will host a Key Opinion Leader ...
AC Immune (NASDAQ: ACIU ) announces that Genentech, a member of the Roche Group ( OTCQX:RHHBY ), has initiated a substudy in the ongoing Phase 2 Alzheimer’s Prevention Initiative (API) trial of AC Immune’s, crenezumab. More news on: AC Immune SA, Roche Holding AG, Healthcar...
LAUSANNE, Switzerland, June 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Genentech, a member of the Roche Group, has initiated a substudy in...
Alzheimer's Disease Alzheimer's disease is a devastating neuro-degenerative disease, one of the common forms of dementia. About 80 percent of dementia cases are caused by Alzheimer’s disease. Named after the German psychiatrist Alois Alzheimer, the disease is currently diagnose...
AC Immune (NASDAQ: ACIU ): Q1 Non-GAAP EPS of CHF0.85; GAAP EPS of CHF0.91. More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more ...
LAUSANNE, Switzerland, May 15, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering Precision Medicine in neurodegenerative diseases, today announced financial results for the first quarter ...
News, Short Squeeze, Breakout and More Instantly...
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partner ...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...